Yeh is director of the UNC Lineberger Pancreatic Cancer Center of Excellence and professor of surgery and pharmacology at UNC School of Medicine. In addition, she is the vice chair for research in the Department of Surgery.
“It is an honor to be considered for the PanCAN’s scientific and medical advisory board. PanCAN board and its leaders have been at the forefront of promoting advances in clinical care and innovation,” Yeh said. “Although we have seen many advances in pancreatic cancer over the last decade, there is still so much that we need to do for patients and their families. I am excited to help advocate for integrating the myriad innovative research and clinical care to accelerate advances in this still deadly cancer.”
PanCAN’s scientific and medical advisory board is comprised of leading scientists, clinicians and healthcare professionals who specialize in pancreatic cancer from institutions across the United States. The board members provide scientific and clinical expertise to guide PanCAN in planning and implementing its research initiatives, as well as its in-depth information, resources and services for patients, caregivers, and healthcare professionals.
“Our [scientific and medical advisory board] is made up of some of the most accomplished scientists and medical professionals in the field, representing the nation’s leading institutions and high-volume centers for pancreatic cancer,” said Julie Fleshman, JD, MBA, PanCAN president and CEO. “Our goal is to improve patient outcomes through advanced research, better early detection strategies, improved treatment options and ensuring patients receive the best care.”
Founded in 1999, PanCAN is dedicated to improving the lives of everyone impacted by pancreatic cancer by advancing scientific research, building community, sharing knowledge and advocating for patients.